
Quick Links
You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
                                    Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa | 
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa | 
|---|---|---|---|---|---|---|
–与化疗相比,接受enfortumab vedotin 联合pembrolizumab治疗的患者死亡风险降低了53% – –与化疗相比,enfortumab vedotin 与...
Read more about 突破性的EV-302临床研究显著延长了接受enfortumab vedotin-ejfv和 pembrolizumab一线治疗晚期膀胱癌患者的总生存期和无进展生存期
-该项投资将提升安斯泰来的全球市场供应能力,并加快创新药物的开发及商业化-...
东京,2023年7月13日--安斯泰来制药集团(TSE:4503,总裁兼首席执行官:冈村直树,“安斯泰来”)今天宣布,欧洲药品管理局(EMA)已受理公司提出
在安斯泰来,我们致力于供应商的多元化,与不同的供应商开展良好合作。多元化供应商大多由占比较低的个人或群体经营,如女性所有的企业、由
